Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 18/20 | 0.58 |
| ▸ | EDNRA | P25101 | 18/20 | 0.58 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065700 | 0.92 | EDNRB (0.58) | EDNRBEDNRA | |
| SCHEMBL7069236 | 0.89 | EDNRA (0.60) | EDNRBEDNRA | |
| SCHEMBL7068867 | 0.87 | EDNRB (0.54) | EDNRBEDNRA | |
| SCHEMBL7068554 | 0.85 | EDNRA (0.60) | EDNRBEDNRA | |
| SCHEMBL7069698 | 0.83 | EDNRB (0.52) | EDNRBEDNRA | |
| SCHEMBL7071791 | 0.82 | EDNRA (0.62) | EDNRBEDNRA | |
| SCHEMBL7065627 | 0.80 | EDNRA (0.58) | EDNRBEDNRA | |
| SCHEMBL7065436 | 0.79 | EDNRB (0.38) | EDNRBEDNRA | |
| SCHEMBL7069377 | 0.79 | EDNRB (0.39) | EDNRBEDNRA | |
| SCHEMBL7066032 | 0.76 | EDNRA (0.59) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-0790993-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | claimed |
| WO-1996015125-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | claimed |
| US-5482960-A | Nonpeptide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| WO-1996015125-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5482960-A | Nonpeptide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885CTSD 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.